Intestinal epithelium functions as a tissue barrier to prevent interaction between the internal compartment and the external milieu. Intestinal barrier function also determines epithelial polarity for the absorption of nutrients and the secretion of waste products. These vital functions require strong integrity of tight junction proteins. In fact, intestinal tight junctions that seal the paracellular space can restrict mucosal-to-serosal transport of hostile luminal contents. Tight junctions can form both an absolute barrier and a paracellular ion channel. Although defective tight junctions potentially lead to compromised intestinal barrier and the development and progression of gastrointestinal (GI) diseases, no FDA-approved therapies that recover the epithelial tight junction barrier are currently available in clinical practice. Here, we discuss the impacts and regulatory mechanisms of tight junction disruption in the gut and related diseases. We also provide an overview of potential therapeutic targets to restore the epithelial tight junction barrier in the GI tract.
Intestinal tight junction disruption contributes to the pathogenesis of inflammatory bowel diseases (IBD). We have recently reported that gallic acid was able to enhance intestinal tight junction assembly via CaMKK-β/AMPK/SIRT-1/ERK-dependent mechanisms with unknown possible therapeutic applications in IBD. The main aims of this study are to investigate the in vivo effects of gallic acid in experimental colitis mice and to search for feasible mechanisms of action. Here, we found that gallic acid attenuated weight loss, reduced disease activity index, and reversed colon length shortening in DSS-induced colitis mice. Importantly, gallic acid also significantly increased survival rates of DSS-induced colitis mice. Based on histopathological analyses, gallic acid diminished immune cell infiltration and neutrophil activity in colitis tissues. Of particular interest, gallic acid significantly reduced gene expressions of proinflammatory cytokines, including TNF, IFN-γ, IL-1β, IL-6, and IL-8. In addition, gallic acid suppressed MLCK gene transcription and protein expression in DSS-induced colitis mice. Furthermore, gallic acid also enhanced the expression of tight junction proteins, including ZO-1 and occludin. Consistently, gallic acid reduced tight junction-dependent leak pathway permeability and was shown to increase SIRT-1 activity, AMPK, and ERK phosphorylation in colon tissues of DSS-induced colitis mice. This study not only explores anti-colitogenic impacts of gallic acid, but also sheds some light on the mechanisms of its action. According to our findings, gallic acid may be useful as an anti-colitogenic nutraceutical.
31 July 2024 in Molecular Nutrition & Food Research
Madecassoside, one of the main bioactive compounds found in Centella asiatica extract, has long been used in the cosmetic regime for skin care with doubtful effects. The main objectives of this study are to investigate the effects of Madecassoside on skin wound healing, UVB-induced keratinocyte damages, and to search for its pharmacological mechanism. Here, using fully differentiated keratinocyte-like HaCaT cell monolayers as an in vitro model, we found that Madecassoside enhanced wound healing and protected against UVB-induced keratinocyte apoptosis and reduction of cell viability. Indeed, these pharmacological effects of Madecassoside were completely abolished by pretreatment of an intracellular Ca2+ chelator (BAPTA), inhibitors of AMP-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), and extracellular signal-regulated kinase (ERK). In addition, our Western blotting analyses strongly indicated that Madecassoside-induced ERK phosphorylation was suppressed by pretreatment of BAPTA, inhibitors of AMPK and mTOR signaling. Collectively, these data suggested that Madecassoside promotes wound healing and reduces keratinocyte apoptosis after being damaged by UVB radiation, at least in part, via Ca2+/AMPK- and mTOR-dependent ERK phosphorylation.